Drawing on years of prior research, a new paper published recently in The Journal of Clinical Endocrinology & Metabolism makes the case for a wider classification of a complex disease such as type 2 diabetes. A new series of subsets would take into account race, age at onset, and a host of other contributing factors....
Phase 3 Trial Results Show Promise for Drug to Treat Severe Hypoglycemia
Earlier this week Diabetes Care published results from a Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. Zealand Pharma is marketing the drug as Zegalogue. The study found that dasiglucagon administration resulted in a reversal of hypoglycemia (with a median recovery time of 10 minutes) with 99% of...
Recently, Metro Health – University of Michigan Health, an affiliate of University of Michigan Health, announced that it reduced incidence of hypoglycemia by more than 54% and experienced a 40% decline in hyperglycemia since implementing personalized insulin dosing software. Glytec is marketing the software as the eGlycemic Management System® (eGMS). Extensive research links poor glycemic control...
Proof-of-Concept Study Shows CGM Benefit in Patients with COVID-19
A proof-of-concept study recently published in Diabetes Care shows how inpatient diabetes technology is advancing and can provide meaningful improvements in care today and in a post-pandemic world. The research team, led by Francisco J. Pasquel, MD, MPH, assistant professor of medicine in the Division of Endocrinology at Emory University in Atlanta, write that point-of-care...
Tubeless Automated Insulin Delivery Improves Blood Glucose Outcomes
Study finds Omnipod® 5 simplifies diabetes management in type 1 diabetes People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod,...
Phase 2 clinical trial results show fewer episodes of low blood sugar and comparable safety A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical trial. The study results, which were presented at...
Cram Session: The Endocrine Society’s New Online CGM Program
Endocrine News speaks with Vivian A. Fonseca, MD, FRCP, and Pamela Kushner, MD, FAAFP, to learn more about the Endocrine Society’s new CME program, “Continuous Glucose Monitoring: Merging Patient Satisfaction with Data-Driven Glycemic Control.” As Endocrine News showed in its December 2020 issue, breakthroughs in endocrine science and research continue to take place at a...
Factors Other than Gestational Weight Gain Linked to Metabolic Complications of Pregnancy
Factors other than how much weight a woman gains during pregnancy may contribute to metabolic complications such as gestational diabetes (GDM), according to a paper recently published in Journal of the Endocrine Society. Researchers led by Fernanda L. Alvarado, MD, of the Mother Infant Research Institute at Tufts Medical Center in Boston, Mass., point out...
